PharmiWeb.com - Global Pharma News & Resources

Pharmaco - Press Releases

Date Title Company
03-Jul-2024 LEO Pharma, Allergy UK and Expert Taskforce Uncover the Real Burden of Living with Chronic Hand Eczema (CHE) in New Report LEO Pharma
03-Jul-2024 Nyxoah Has Signed a €37.5 Million Loan Facility Agreement with the European Investment Bank Nyxoah SA.
03-Jul-2024 Pentixapharm Acquires Target Discovery Business of Glycotope Pentixapharm AG
03-Jul-2024 CureVac Initiates Strategic Restructuring to Align Resources with Focus on High-Value mRNA Pipeline Opportunities CureVac
03-Jul-2024 GSK and CureVac to Restructure Collaboration into New Licensing Agreement CureVac
03-Jul-2024 Cantourage Group SE: Strong growth continues – another monthly sales record in June 2024 Cantourage Group SE
02-Jul-2024 Mainz Biomed Provides Half Year 2024 Corporate Update Mainz BioMed N.V.
02-Jul-2024 CPHI returns to the Messe Frankfurt in 2025 Informa Markets
02-Jul-2024 Valneva receives marketing authorisation in Europe for world’s first Chikungunya vaccine Valneva
02-Jul-2024 Siegfried successfully completes acquisition of an early-phase CDMO in Wisconsin (US) Siegfried AG
01-Jul-2024 Nipocalimab pivotal Phase 3 trial demonstrates sustained disease control in FcRn class for a broad population of myasthenia gravis patients Janssen-Cilag International NV
01-Jul-2024 Pentixapharm Announces Expansion of Supervisory Board with the Appointment of Distinguished Endocrinologist Marcus Quinkler Pentixapharm AG
01-Jul-2024 CS MEDICA Stock Now Also Traded on XETRA CS MEDICA A/S
01-Jul-2024 “Hauptstadtkongress 2024”: Medios hosts symposium on 'Security of supply” Medios AG
01-Jul-2024 Biotest prepares launch of its immunoglobulin Yimmugo in the USA, establishing a framework for a strategic billion-dollar distribution agreement with Kedrion Biotest AG
01-Jul-2024 DEFENCE’S ACCUTOX BOOSTS AND SYNERGIZES WITH IMMUNE CHECKPOINT INHIBITORS Defence Therapeutics Inc.
01-Jul-2024 Lonza Welcomes New Group Chief Executive Officer Wolfgang Wienand Lonza Group AG
01-Jul-2024 Biophytis presented its Phase 2-3 COVA study results in severe forms of Covid-19 at the WCID in Paris Biophytis
01-Jul-2024 Formycon receives FDA approval for FYB203/AHZANTIVE®1) (aflibercept-mrbb), a biosimilar to Eylea®2) Formycon AG
28-Jun-2024 FDA grants approval for Eylea®1) biosimilar FYB203/AHZANTIVE®2) (aflibercept-mrbb) Formycon AG